Want to see JP:197A full AI Analyst Report?
197A Stock Chart & Stats
¥509.00
¥4.00(0.67%)
At close: 4:00 PM EST
¥509.00
¥4.00(0.67%)
Day’s Range― - ―
52-Week Range¥463.00 - ¥577.00
Previous CloseN/A
Volume864.10K
Average Volume (3M)250.99K
Market Cap
¥54.74B
Enterprise Value¥68.05K
Total Cash (Recent Filing)¥3.56B
Total Debt (Recent Filing)¥21.26B
Price to Earnings (P/E)9.8
Beta0.44
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.44%
Share Statistics
EPS (TTM)52.39
Shares Outstanding106,702,350
10 Day Avg. Volume152,610
30 Day Avg. Volume250,990
Financial Highlights & Ratios
PEG Ratio-0.57
Price to Book (P/B)2.55
Price to Sales (P/S)3.45
P/FCF Ratio-7.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)32.58
Revenue Forecast (FY)¥17.98B
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilitySustained gross and operating profitability, together with a substantially higher net margin, indicates strong earnings capacity. This provides internal funding potential and resilience, although operating-margin trends should continue to be monitored.
High Return On EquityHigh returns generated on shareholder capital indicate that the company has historically converted its equity base into meaningful profits. This supports capital efficiency and can strengthen long-term value creation if leverage remains controlled.
Positive Asset GrowthPositive asset growth suggests the company is expanding its operating or resource base rather than experiencing balance-sheet contraction. This may support future capacity and development, provided growth is matched by sustainable cash generation.
Bears Say
Volatile Cash GenerationRepeated swings between positive and negative operating cash flow weaken earnings quality and make funding needs harder to predict. If volatility persists, the company may rely more heavily on debt or working-capital management.
Rising LeverageThe sharp increase in debt and debt-to-equity above 1.0 reduce financial flexibility. Higher leverage increases sensitivity to earnings or cash-flow weakness and can constrain investment capacity if funding conditions deteriorate.
Uneven Revenue And Margin TrendsUneven revenue performance indicates demand may be volatile, while recent operating-margin compression raises questions about profit durability. Sustained growth and margin recovery are needed to demonstrate that strong net income can persist.
Tauns Laboratories, Inc. News
197A FAQ
What was Tauns Laboratories, Inc.’s price range in the past 12 months?
Tauns Laboratories, Inc. lowest stock price was ¥463.00 and its highest was ¥577.00 in the past 12 months.
What is Tauns Laboratories, Inc.’s market cap?
Tauns Laboratories, Inc.’s market cap is ¥54.74B.
When is Tauns Laboratories, Inc.’s upcoming earnings report date?
Tauns Laboratories, Inc.’s upcoming earnings report date is Nov 12, 2026 which is in 57 days.
How were Tauns Laboratories, Inc.’s earnings last quarter?
Tauns Laboratories, Inc. released its earnings results on Aug 13, 2026. The company reported ¥28.92 earnings per share for the quarter.
Is Tauns Laboratories, Inc. overvalued?
According to Wall Street analysts Tauns Laboratories, Inc.’s price is currently Overvalued.
Does Tauns Laboratories, Inc. pay dividends?
Tauns Laboratories, Inc. pays a Semiannually dividend of ¥14.5 which represents an annual dividend yield of 5.44%. See more information on Tauns Laboratories, Inc. dividends here
What is Tauns Laboratories, Inc.’s EPS estimate?
Tauns Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tauns Laboratories, Inc. have?
Tauns Laboratories, Inc. has 106,702,350 shares outstanding.
What happened to Tauns Laboratories, Inc.’s price movement after its last earnings report?
Tauns Laboratories, Inc. reported an EPS of ¥28.92 in its last earnings report. Following the earnings report the stock price went down -0.416%.
Which hedge fund is a major shareholder of Tauns Laboratories, Inc.?
Currently, no hedge funds are holding shares in JP:197A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tauns Laboratories, Inc.
TAUNS Laboratories, Inc. is a company dedicated to the creation and production of in-vitro diagnostic pharmaceuticals and various types of measuring equipment. Additionally, the firm facilitates the international trade (import and export) of an extensive selection of instruments, covering industrial, medical, physical, and chemical measurement applications. Founded in April 1987, the company maintains its principal office in Izunokuni, Japan.
Technical Analysis
Shin Nippon Biomedical Laboratories, Ltd.
―
Eiken Chemical Co., Ltd.
―
JCR Pharmaceuticals Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Kitazato Corporation
―